• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Pharmaceutical Company to Pay $95M to Settle Allegations of Improper Drug Promotion

Article

Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle allegations that the company promoted three drugs for uses that were not medically accepted, the government announced Thursday.

The Justice Department said the three are the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease drug Combivent and the high-blood-pressure drug Micardis.

Read the full story: http://wapo.st/R32A1a

Source: The Washington Post

Related Videos
Ciara Zachary, PhD, MPH
Eleanor Perfetto, PhD
William Schpero, PhD, MPhil, MPH
Oncology experts at PCOC
Susan Cantrell, CEO of AMCP
Susan Cantrell, CEO of AMCP
Kelley L. Julian, PharmD, BCOP
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.